Product Reports Resources Pricing Login Book a demo

Five Prime Therapeutics

Biotech & Life Sciences · South San Francisco, United States · Founded 2001 · IPO 2013

Innovative Protein Therapeutics

Valuation $1.90B
Revenue $12M

Talent graph

Five Prime Therapeutics's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Five Prime Therapeutics's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series B+ 7 investors entered at this stage
HealthCap
Wellcome Trust
Kleiner Perkins
Versant Ventures
Advanced Technology Ventures
Domain Associates
Diamond Capital Company

Global footprint

Where Five Prime Therapeutics has talent and traffic

Workforce by country
🇺🇸 United States · South San Francisco HQ
Book a demo for the full country breakdown

Patent intelligence

Five Prime Therapeutics’s patent portfolio

Estimated portfolio value
$123M

51 active families in the valuation dataset.

Source: Dealroom Patent Intelligence · PatSnap. Portfolio estimates and the family records below have different coverage.

Compare patent portfolios across companies →

Market sentiment

What the market is saying about Five Prime Therapeutics

An AI-synthesized read of the highest-engagement posts about Five Prime Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Five Prime Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.